Cross-Subtype T-Cell Immune Responses Induced by a Human Immunodeficiency Virus Type 1 Group M Consensus Env Immunogen

ABSTRACT The genetic diversity among globally circulating human immunodeficiency virus type 1 (HIV-1) strains is a serious challenge for HIV-1 vaccine design. We have generated a synthetic group M consensus env gene (CON6) for induction of cross-subtype immune responses and report here a comparative study of T-cell responses to this and natural strain env immunogens in a murine model. Three different strains of mice were immunized with CON6 as well as subtype A, B, or C env immunogens, using a DNA prime-recombinant vaccinia virus boost strategy. T-cell epitopes were mapped by gamma interferon enzyme-linked immunospot analysis using five overlapping Env peptide sets from heterologous subtype A, B, and C viruses. The CON6-derived vaccine was immunogenic and induced a greater number of T-cell epitope responses than any single wild-type subtype A, B, and C env immunogen and similar T-cell responses to a polyvalent vaccine. The responses were comparable to within-clade responses but significantly more than between-clade responses. The magnitude of the T-cell responses induced by CON6 (measured by individual epitope peptides) was also greater than the magnitude of responses induced by individual wild-type env immunogens. Though the limited major histocompatibility complex repertoire in inbred mice does not necessarily predict responses in nonhuman primates and humans, these results suggest that synthetic centralized env immunogens represent a promising approach for HIV-1 vaccine design that merits further characterization.

[1]  R. Bollinger,et al.  Cross-clade T lymphocyte-mediated immunity to HIV type 1: implications for vaccine design and immunodetection assays. , 2002, AIDS research and human retroviruses.

[2]  P. Doherty,et al.  Limited Breadth of a T-Helper Cell Response to a Human Immunodeficiency Virus Envelope Protein , 2003, Journal of Virology.

[3]  J. Mascola,et al.  Multiclade Human Immunodeficiency Virus Type 1 Envelope Immunogens Elicit Broad Cellular and Humoral Immunity in Rhesus Monkeys , 2005, Journal of Virology.

[4]  Brian T. Foley,et al.  HIV Sequence Compendium 2018 , 2010 .

[5]  R. Insel.  Potential Alterations in Immunogenicity by Combining or Simultaneously Administering Vaccine Components a , 1995, Annals of the New York Academy of Sciences.

[6]  Feng Gao,et al.  A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses. , 2006, Virology.

[7]  D. Montefiori,et al.  Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. , 1999, Science.

[8]  D. Nickle,et al.  Consensus and Ancestral State HIV Vaccines , 2003, Science.

[9]  N. K. Steede,et al.  Allocation of Helper T-cell Epitope Immunodominance According to Three-dimensional Structure in the Human Immunodeficiency Virus Type I Envelope Glycoprotein gp120* , 2001, The Journal of Biological Chemistry.

[10]  F. Vannberg,et al.  Human Immunodeficiency Virus Type 1 Subtype C Molecular Phylogeny: Consensus Sequence for an AIDS Vaccine Design? , 2002, Journal of Virology.

[11]  B. Korber,et al.  HIV type 1 V3 region primer-induced antibody suppression is overcome by administration of C4-V3 peptides as a polyvalent immunogen. , 1995, AIDS research and human retroviruses.

[12]  D. Strick,et al.  Comprehensive Epitope Analysis of Human Immunodeficiency Virus Type 1 (HIV-1)-Specific T-Cell Responses Directed against the Entire Expressed HIV-1 Genome Demonstrate Broadly Directed Responses, but No Correlation to Viral Load , 2003, Journal of Virology.

[13]  S. Osmanov,et al.  Identification of highly conserved and broadly cross-reactive HIV type 1 cytotoxic T lymphocyte epitopes as candidate immunogens for inclusion in Mycobacterium bovis BCG-vectored HIV vaccines. , 2000, AIDS research and human retroviruses.

[14]  Eric R. Ziegel,et al.  Generalized Linear Models , 2002, Technometrics.

[15]  Scott A. Brown,et al.  Clustering of Th Cell Epitopes on Exposed Regions of HIV Envelope Despite Defects in Antibody Activity 1 , 2003, The Journal of Immunology.

[16]  P. McCullagh,et al.  Generalized Linear Models , 1992 .

[17]  P. Doherty,et al.  Localization of CD4+ T cell epitope hotspots to exposed strands of HIV envelope glycoprotein suggests structural influences on antigen processing , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[18]  B. Wahrén,et al.  Interactions of single and combined human immunodeficiency virus type 1 (HIV-1) DNA vaccines. , 2001, Virology.

[19]  J. Sodroski,et al.  Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody , 1998, Nature.

[20]  L. Weinberger,et al.  Dramatic Rise in Plasma Viremia after CD8+ T Cell Depletion in Simian Immunodeficiency Virus–infected Macaques , 1999, The Journal of experimental medicine.

[21]  G. Nabel,et al.  Immunogenicity of Multiple Gene and Clade Human Immunodeficiency Virus Type 1 DNA Vaccines , 2003, Journal of Virology.

[22]  Henryk Mach,et al.  Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity , 2002, Nature.

[23]  D. Montefiori,et al.  Polyvalent Envelope Glycoprotein Vaccine Elicits a Broader Neutralizing Antibody Response but Is Unable To Provide Sterilizing Protection against Heterologous Simian/Human Immunodeficiency Virus Infection in Pigtailed Macaques , 2001, Journal of Virology.

[24]  M. McElrath,et al.  Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[25]  A. Lapedes,et al.  Timing the ancestor of the HIV-1 pandemic strains. , 2000, Science.

[26]  M. Ackers,et al.  Generation of a consensus sequence from prevalent and incident HIV-1 infections in West Africa to guide AIDS vaccine development. , 2002, Virology.

[27]  A. Simon,et al.  Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. , 2000, Science.

[28]  P. Earl,et al.  Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. , 2002, Vaccine.

[29]  Bette T. Korber,et al.  Antigenicity and Immunogenicity of a Synthetic Human Immunodeficiency Virus Type 1 Group M Consensus Envelope Glycoprotein , 2005, Journal of Virology.

[30]  Søren Brunak,et al.  Clustering Patterns of Cytotoxic T-Lymphocyte Epitopes in Human Immunodeficiency Virus Type 1 (HIV-1) Proteins Reveal Imprints of Immune Evasion on HIV-1 Global Variation , 2002, Journal of Virology.

[31]  Martine Peeters,et al.  Unprecedented Degree of Human Immunodeficiency Virus Type 1 (HIV-1) Group M Genetic Diversity in the Democratic Republic of Congo Suggests that the HIV-1 Pandemic Originated in Central Africa , 2000, Journal of Virology.

[32]  J. Berzofsky,et al.  Broad recognition of cytotoxic T cell epitopes from the HIV-1 envelope protein with multiple class I histocompatibility molecules. , 1992, Journal of immunology.

[33]  Feng Gao,et al.  Diversity Considerations in HIV-1 Vaccine Selection , 2002, Science.

[34]  J. Mascola,et al.  Expanded breadth of virus neutralization after immunization with a multiclade envelope HIV vaccine candidate. , 2005, Vaccine.

[35]  D. Nickle,et al.  Human Immunodeficiency Virus Type 1 Subtype B Ancestral Envelope Protein Is Functional and Elicits Neutralizing Antibodies in Rabbits Similar to Those Elicited by a Circulating Subtype B Envelope , 2005, Journal of Virology.

[36]  Nicole Frahma,et al.  HIV Molecular Immunology 2005 , 2006 .

[37]  Robert H. Kushler,et al.  Statistical Computing: An Introduction to Data Analysis Using S-PLUS , 2003, Technometrics.

[38]  Michael J. Crawley,et al.  Statistical Computing: An Introduction to Data Analysis using S-Plus , 2002 .